Miniaturised optically accessible bioreactor for drug discovery and biological research

Informazioni relative al progetto

MOAB

ID dell’accordo di sovvenzione: 825159

DOI 10.3030/825159

Progetto concluso

Data della firma CE 21 Agosto 2018

Data di avvio 1 Dicembre 2018

Data di completamento 31 Luglio 2020

Finanziato da

• EXCELLENT SCIENCE - European Research Council (ERC)

Costo totale € 150 000,00

Contributo UE € 150 000,00

Coordinato da

POLITECNICO DI MILANO
Italy

Obiettivo

The problem that we address is that the pharmaceutical companies do not develop radically new drugs anymore, because the development process lasts ten years and costs around one billion euro. Development of a new drug is subjected to regulatory approvals following three demonstrations: lab discovery in vitro, animal testing in vivo and clinical trial on patients. This process has 99.9% overall failure, of which 96.4% because the drug efficacy measured in vitro is not confirmed in animals. In fact, the most widespread technology used to test therapeutic agents in vitro, a flat culture dish in which single cell populations are cultured and the drug to be tested is added to the culture, is obsolete. In many pathologies such as cancer and neurodegeneration, in vivo response to drugs is based on complex interactions, occurring in three-dimensions (3D) between several cell populations. To solve this problem, in the context of an ERC consolidator grant (CoG) that I currently lead, I integrated a novel nano-patterned 3D substrate for stem cell culture, called the “nichoid”, into an existing miniaturised optically accessible bioreactor (MOAB). The MOAB allows to culture 3D organoids of few millimetres in size, under continuous perfusion of the culture medium, infusion of the drug to be tested and diagnostics of cell response both in real time and also post-cultivation. Both the original inventions (the nichoid and the MOAB) are covered by Italian patents originated in the frame of the CoG project and already extended as PCT. The goal of this PoC proposal is to perform a technical and commercial feasibility to move to the market the MOAB device integrating the nichoid-patterned substrate. I will characterize the fluid-dynamics of the bioreactor chamber that has been modified to accommodate the nichoid substrate. Also, I will set a market assessment and an actionable IPR strategy with identification of a suitable exploitation strategy for valorising the patent/know how.

Campo scientifico

• scienze mediche e della salute › medicina di base › farmacologia e farmacia › scoperta di farmaci
• ingegneria e tecnologia › biotecnologia ambientale › biorisanamento › bioreattori
• scienze mediche e della salute › biotecnologia medica › tecnologie cellulari › cellule staminali
• scienze mediche e della salute › medicina clinica › oncologia
• scienze mediche e della salute › medicina di base › patologia

Programma(i)

• H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC) Main Programme

Argomento(i)

• ERC-2018-PoC - ERC Proof of Concept Grant

Invito a presentare proposte

ERC-2018-PoC

Meccanismo di finanziamento

ERC-POC - Proof of Concept Grant

Coordinatore

POLITECNICO DI MILANO

• Contribution nette de l'UE: € 105 000,00
• Indirizzo: Piazza leonardo da vinci 32 ; 20133 Milano ; Italia
• Regione: Nord-Ovest › Lombardia › Milano
• Tipo di attività: Higher or Secondary Education Establishments
• Altri finanziamenti: € 0,00

Beneficiari (2)

POLITECNICO DI MILANO

Italia

• Contribution nette de l'UE: € 105 000,00
• Indirizzo: Piazza leonardo da vinci 32 ; 20133 Milano
• Regione: Nord-Ovest › Lombardia › Milano
• Tipo di attività: Higher or Secondary Education Establishments
• Altri finanziamenti: € 0,00

UNIVERSITA' DEGLI STUDI DI BERGAMO

Italia

• Contribution nette de l'UE: € 45 000,00
• Indirizzo: Via salvecchio 19 ; 24129 Bergamo
• Regione: Nord-Ovest › Lombardia › Bergamo
• Tipo di attività: Higher or Secondary Education Establishments
• Altri finanziamenti: € 0,00